ORTHOCELL LTD's stock soared 7.84% during intraday trading on Friday.
The surge followed the company's announcement that the first surgical case using its nerve repair product, Remplir, has been completed at a military base hospital within the US Department of Defense/Veterans Affairs hospital network. This milestone represents a significant step in Orthocell's US commercialization strategy for the product.